ClinicalTrials.gg
Active, not recruitingNCT07017179Updated Sep 29, 2026

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

A Phase 2 interventional study of AZD6234 and Placebo in Obesity/Overweight, sponsored by AstraZeneca. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing AZD6234 in Obesity — 2 open to participants now, 4 under way, 1 of them phase 3. AZD6234 · Obesity.

Enrollment
10th of 10
16 · median 85
Started
2025
with 4 others
Phase 2
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
AstraZeneca

Among the 10 studies testing AZD6234 in Obesity, this one is the 10th largest by enrollment, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies testing AZD6234 in Obesity are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About AZD6234

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing AZD6234 in Obesity, or all of them as a file.
02

Study summary

This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.

Read the detailed description

This is a Phase Ⅱa, multi-centre, multi-drug, platform study in Chinese participants living with obesity/overweight. This platform study will consist of several sub-studies. Eligible participants will be allocated to one sub-study to receive the study intervention(s). Each sub-study will consist of a screening period, a treatment period, and a follow-up period.

Sub-study 1: AZD6234 Monotherapy This study will explore the safety, tolerability, pharmacokinetic (PK), efficacy, and immunogenicity of AZD6234 in Chinese participants with obesity/overweight, approximate 18 participants will be randomised in sub-study 1. The sub-study will comprise 3 periods totalling up to approximately 23 weeks.

Sub-study 2: AZD9550 Monotherapy and AZD6234 in combination with AZD9550 This study will explore the safety, tolerability, PK, efficacy, and immunogenicity of AZD9550 and of AZD6234 in combination with AZD9550 in Chinese participants with obesity/overweight, approximately 30 participants will be randomised in sub-study 2 (15 in Cohort A and 15 in Cohort B). The sub-study will comprise 3 periods totalling up to approximately 35 weeks.

03

Conditions studied

  • Obesity/Overweight

Keywords

  • Obesity
  • Overweight
  • Chinese Participants
  • AZD6234
  • AZD9550
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 55 years.
  2. ≥ 27 kg/m2.
  3. Stable body weight for 3 months prior to screening.
  4. Male and female ( use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies).
  5. Participants should refrain from blodd donation throughout the sub-study, including the follow-up period.
  6. Negative pregnancy test at screening and randomisation for FOCBP and must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening.
  2. History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control.
  3. Treatment with diabetes medication in past 3 months prior to screening.
  4. ≥ 6.5% (48 mmol/mol) at screening.
  5. Gastroparesis (or similar) requiring treatment.
  6. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract.
  7. Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:

    1. ≥ 2.5 ×
    2. ALT ≥ 2.5 × ULN
    3. TBL ≥ 1.5 × ULN.
  8. Prior history of cholecystectomy or untreated cholelithiasis.
  9. History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × ULN at screening.
  10. Severely uncontrolled hypertension defined as systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on the average of 2 seated measurements after being at rest for at least 5 minutes.
  11. HR \< 50 bpm or > 100 bpm after being at rest for 5 minutes.
  12. Impaired renal function defined as ≤ 45 mL/minute/1.73 m2 at screening (GFR estimated according to CKD-EPI).
  13. History of psychosis or bipolar disorder.
  14. Severe vitamin D deficiency defined as a 25-OH vitamin D level \< 12 ng/mL.
  15. Uncontrolled thyroid disease, defined as TSH > ULN or \< LLN for the laboratory reference range, as judged by the PI at screening.

    Sub-study 2 only

  16. Personal or family history (first-degree relative) of MTC or MEN2.
  17. History of marijuana or THC use within 3 months before screening, or unwilling/unable to abstain from marijuana or THC use during the study.
  18. Previous hospitalisation for any psychiatric reason.
  19. PHQ-9 score ≥ 15 within the 2 years prior to screening or at screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    AZD6234 (sub-study 1)

    Participants will receive subcutaneous injection of AZD6234 on Day 1 and continue for 16 weeks.

    Drug: AZD6234

  • Placebo comparator
    Placebo (sub-study 1)

    Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 16 weeks.

    Drug: Placebo

  • Experimental
    AZD9550(sub-study 2 Cohort A)

    Participants will receive subcutaneous injection of AZD9550 on Day 1 and continue for 28 weeks.

    Drug: AZD9550

  • Placebo comparator
    Placebo (sub-study 2 Cohort A)

    Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks.

    Drug: Plocebo

  • Experimental
    AZD6234 in combination with AZD9550 (sub-study 2 Cohort B)

    Participants will receive subcutaneous injection of AZD6234 and AZD9550 on Day 1 and continue for 28 weeks.

    Drug: AZD6234 in combination with AZD9550

  • Placebo comparator
    Placebo (sub-study 2 Cohort B)

    Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks.

    Drug: Placebo

Interventions

  • Participants will receive a subcutaneous injection weekly

  • DrugPlacebo

    Participants will receive a subcutaneous injection weekly.

  • Participants will receive a subcutaneous injection weekly

  • DrugPlocebo

    Participants will receive a subcutaneous injection weekly

  • DrugAZD6234 in combination with AZD9550

    Participants will receive a subcutaneous injection weekly

  • DrugPlacebo

    Participants will receive a subcutaneous injection weekly

06

What researchers measure

Primary outcomes

  1. Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).

    To assess the safety and tolerability of repeated subcutaneous(SC) doses of AZD6234 compared to placebo.

    Time frame: From baseline to Day 141

  2. Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2).

    To assess the safety and tolerability of repeated SC doses of AZD9550 and AZD6234 in combination with AZD9550 compared to placebo.

    Time frame: From baseline to Day 225

Secondary outcomes

  1. PK parameters : Cmax (sub-study 1)

    To characterise the PK of AZD6234 following repeated subcutaneous (SC) doses.

    Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.

  2. PK parameters : Tmax (sub-study 1)

    To characterise the PK of AZD6234 following repeated SC doses.

    Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.

  3. PK parameters : AUClast (sub-study 1)

    To characterise the PK of AZD6234 following repeated SC doses.

    Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.

  4. PK parameters : AUCtau (sub-study 1)

    To characterise the PK of AZD6234 following repeated SC doses.

    Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.

  5. Percent change in body weight from baseline to Week 16 (sub-study 1)

    To assess the effects of AZD6234 on the body weight change from baseline with and without placebo correction.

    Time frame: From baseline to Week 16

  6. Incidence of ADA to AZD6234 (sub-study 1).

    To evaluate the immunogenicity of AZD6234 following repeated SC doses.

    Time frame: Day 1 to Day 141

  7. ADA titer of AZD6234 (sub-study 1).

    To evaluate the immunogenicity of AZD6234 following repeated SC doses.

    Time frame: Day 1 to Day 141

  8. PK parameters : Cmax (sub-study 2 Cohort A)

    To characterise the PK of AZD9550 following repeated SC doses.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).

  9. PK parameters : Tmax (sub-study 2 Cohort A)

    To characterise the PK of AZD9550 following repeated SC doses.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).

  10. PK parameters : AUClast (sub-study 2 Cohort A)

    To characterise the PK of AZD9550 following repeated SC doses.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).

  11. PK parameters : AUCtau (sub-study 2 Cohort A)

    To characterise the PK of AZD9550 following repeated SC doses.

    Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).

  12. Plasma trough concentration (sub-study 2 Cohort B).

    To characterise the PK of AZD9550 and AZD6234 following repeated SC doses

    Time frame: Day 1 to Day 225

  13. Percent change in body weight from baseline to Week 28 (sub-study 2 ), placebo as comparator

    To assess the effects of AZD9550 and AZD6234 in combination with AZD9550 on the body weight change from baseline with and without placebo correction.

    Time frame: From baseline to Week 28

  14. Percent change in body weight from baseline to Week 28 (sub-study 2, AZD9550 as comparator)

    To assess the effects of AZD6234 in combination with AZD9550 compared to AZD9550 on the body weight change from baseline.

    Time frame: From baseline to Week 28

  15. Incidence of ADA to AZD9550 (sub-study 2).

    To evaluate the immunogenicity of AZD9550 following repeated SC doses.

    Time frame: Day 1 to Day 225

  16. ADA titer of AZD9550 (sub-study 2 Cohort A).

    To evaluate the immunogenicity of AZD9550 following repeated SC doses.

    Time frame: Day 1 to Day 225

  17. Incidence of ADA to AZD6234 and AZD9550 combination therapy (sub-study 2 Cohort B).

    To evaluate the immunogenicity of AZD6234 and AZD9550 following repeated SC combination therapy doses.

    Time frame: Day 1 to Day 225

  18. ADA titer of AZD6234 and AZD9550 combination therapy (sub-study 2 Cohort B).

    To evaluate the immunogenicity of AZD6234 and AZD9550 following repeated SC combination therapy doses.

    Time frame: Day 1 to Day 225

07

Study locations

3 sites
  • Research Site
    Jinan, 250001, China
  • Research Site
    Nanjing, 210011, China
  • Research Site
    Shanghai, 200032, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2026, 17 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 17 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
Jun 12, 2025
StartActual
May 20, 2025
Primary completionEst.
Oct 23, 2026was Aug 2026
CompletionEst.
Oct 23, 2026was Aug 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 6, 2026→Oct 23, 2026
Sep 29, 2026
Study completion
Aug 6, 2026→Oct 23, 2026
Sep 29, 2026
Enrollment
14→16
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Primary completion Aug 6, 2026→Oct 23, 2026
    Study completion Aug 6, 2026→Oct 23, 2026
    Enrollment 14→16
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07017179
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
May 20, 2025
Primary completion
Oct 23, 2026 (estimated)
Completion
Oct 23, 2026 (estimated)
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD6234 · AZD9550

Start the discussion